Loading
A phase 2 trial in lung cancer, run by Ari Raphael, not yet recruiting.
T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer is a phase 2, interventional study registered as NCT06045767 by Ari Raphael, with a registry enrolment figure of 30 participants, started 2024-06 and due to reach its primary completion in 2029-01. Interventions recorded: Pembrolizumab 50 MG Injection [Keytruda]. Conditions listed: Non-small Cell Lung Cancer Metastatic. Primary outcome: Objective Response Rate (ORR) per RECIST 1.1 - correlated to TCR repertoire data, such as clonality/diversity.. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.